A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

NCT07183189 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

576

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SHR-A2009 ; Aumolertinib
DRUG: Aumolertinib

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.